The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), a new once-daily pill developed by Merck, to reduce cholesterol levels in adults with high cholesterol, including those with inherited conditions like heterozygous familial hypercholesterolemia. The approval follows clinical trials showing the drug lowers LDL (bad cholesterol) by 56% to 60% when combined with statin therapy.
Core Facts & Immediate Action
The FDA cleared Lipfendra on July 16, 2024, based on two randomized, double-blind, placebo-controlled trials involving 3,200 adults with severe hypercholesterolemia. The pill targets PCSK9, a protein that affects how the liver removes LDL cholesterol. Common side effects included diarrhea and dizziness, though serious adverse events were similar to placebo.
Deeper Dive & Context
How It Works
Lipfendra blocks PCSK9, preventing it from recycling LDL receptors in the liver. This mechanism differs from statins, which inhibit an enzyme involved in cholesterol production. The drug is intended for patients who do not achieve sufficient cholesterol reduction with statins alone.
Clinical Trial Results
In the trials, participants taking Lipfendra saw 56% to 59% reductions in LDL levels compared to placebo. The FDA noted that the drug was generally well-tolerated, with side effects like diarrhea and dizziness occurring more frequently in the treatment group.
Broader Implications
About 25% of U.S. adults have high LDL levels, according to the American Heart Association (AHA). The AHA recommends lifestyle changes and medications like statins for those with LDL levels above 70 mg/dL. Lipfendra offers an additional treatment option for patients who need further LDL reduction.
Expert Perspectives
Dr. Marc Siegel, a Fox News medical analyst, described PCSK9 as a protein that historically helped humans conserve cholesterol during food scarcity but now contributes to heart disease. He noted that Lipfendra’s impact is roughly double that of statins.
Existing Treatments
Statins remain the most common cholesterol-lowering medication, but some patients require additional therapies. Lipfendra is the first oral PCSK9 inhibitor, offering a new alternative to injectable treatments like PCSK9 inhibitors already on the market.